Generic TOBI Podhaler Availability
Last updated on May 7, 2025.
TOBI Podhaler is a brand name of tobramycin, approved by the FDA in the following formulation(s):
TOBI PODHALER (tobramycin - powder;inhalation)
-
Manufacturer: VIATRIS
Approval date: March 22, 2013
Strength(s): 28MG [RLD]
Is there a generic version of TOBI Podhaler available?
No. There is currently no therapeutically equivalent version of TOBI Podhaler available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of TOBI Podhaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Aerosolization apparatus with capsule puncture alignment guide
Patent 10,207,066
Issued: February 19, 2019
Inventor(s): Dunkley Michael John & Tuckwell Jon David & Vernon-Harcourt Edward William & Glusker Mark & Paboojian Steve
Assignee(s): BGP Products Operations GmbHAn aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. The aerosolization apparatus further comprises a puncturing mechanism within the housing. The puncturing mechanism comprises an alignment guide and a puncture member, wherein the alignment guide comprises a surface adapted to contact the capsule while the puncture member is advanced into the capsule to create an opening in the capsule. At least a portion of the surface is sloped relative to the longitudinal axis of the capsule. Alternatively or additionally, the surface may comprise one or more protrusions. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule. The alignment guide allows for more consistent puncturing of the capsule and a longer lifetime of the apparatus.
Patent expiration dates:
- November 4, 2030✓✓
- November 4, 2030
-
Aerosolization apparatus with air inlet shield
Patent 7,559,325
Issued: July 14, 2009
Inventor(s): Dunkley; Michael John et al.
Assignee(s): Novartis Pharma AG (Basel, CH)An aerosolization apparatus comprises a housing defining a chamber having a plurality of air inlets. The chamber contains an aersolizable pharmaceutical formulation or is sized to receive a receptacle which contains an aerosolizable pharmaceutical formulation. A shield covers at least one of the air inlets or a portion of at least one of the air inlets. The shield prevents blockage of the air inlet by a user grasping the apparatus and inadvertently covering the air inlet. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the receptacle.
Patent expiration dates:
- October 27, 2025✓
- October 27, 2025
-
Methods of treatment of endobronchial infections
Patent 8,664,187
Issued: March 4, 2014
Inventor(s): Challoner Peter & Rodriguez Carlos & Samara Emil & Tarara Thomas E & Lord John D
Assignee(s): Novartis AGThe present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days.
Patent expiration dates:
- June 20, 2025✓
- June 20, 2025
-
Aerosolization apparatus with capsule puncturing member
Patent 8,869,794
Issued: October 28, 2014
Inventor(s): Tuckwell Jon David & St. Quintin Thomas Christopher
Assignee(s): Novartis Pharma AGAn aerosolization apparatus comprises a housing defining a chamber having one or more air inlets. The chamber is sized to receive a capsule which contains an aerosolizable pharmaceutical formulation. A puncturing mechanism is provided within the housing and comprising a puncture member. The puncture member comprises a forward end shaped to form a cutting edge that is effective in cutting the wall of the capsule to create an opening into the capsule. The puncture member also comprises a trailing end shaped so that it has a non-cutting surface that does not cut the wall of the capsule when the trailing end is inserted into the opening created by the forward end. An end section is associated with the housing. The end section is sized and shaped to be received in a user's mouth or nose so that the user may inhale through the end section to inhale aerosolized pharmaceutical formulation that has exited the capsule through the opening created in the capsule.
Patent expiration dates:
- September 12, 2028✓✓
- September 12, 2028
More about TOBI Podhaler (tobramycin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: aminoglycosides
- Breastfeeding
- En español
Patient resources
Other brands
Nebcin, Bethkis, Tobi, Kitabis Pak
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
